GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
GeneDx (WGS) announced its integration with Epic's specialty diagnostics suite, Aura, enabling health systems to order and receive genetic sequencing results directly within their electronic health records (EHR). UNC Health becomes the first health system to implement this integration, with additional health systems now able to access GeneDx's testing services including exome sequencing, whole genome sequencing, and rapid whole genome sequencing.
The integration streamlines the genetic testing process, making results more accessible and visible within patient records. GeneDx has significant experience in genetic testing, having sequenced over 750,000 exomes and genomes, and maintains one of the largest rare disease data sets. The company's services are trusted by 8 out of 10 genetics experts for exome and genome testing.
GeneDx (WGS) ha annunciato la sua integrazione con la suite di diagnostica specialistica di Epic, Aura, permettendo ai sistemi sanitari di ordinare e ricevere i risultati del sequenziamento genetico direttamente all'interno delle loro cartelle cliniche elettroniche (EHR). UNC Health diventa il primo sistema sanitario a implementare questa integrazione, con ulteriori sistemi sanitari ora in grado di accedere ai servizi di test di GeneDx, inclusi il sequenziamento dell'esoma, il sequenziamento del genoma intero e il sequenziamento rapido del genoma intero.
L'integrazione snellisce il processo di testing genetico, rendendo i risultati più accessibili e visibili all'interno delle cartelle dei pazienti. GeneDx ha una significativa esperienza nel test genetico, avendo sequenziato oltre 750.000 esomi e genomi e mantiene uno dei più grandi set di dati sulle malattie rare. I servizi dell'azienda sono fidati da 8 esperti genetisti su 10 per i test dell'esoma e del genoma.
GeneDx (WGS) ha anunciado su integración con el conjunto de diagnósticos especializados de Epic, Aura, permitiendo a los sistemas de salud ordenar y recibir resultados de secuenciación genética directamente dentro de sus registros electrónicos de salud (EHR). UNC Health se convierte en el primer sistema de salud en implementar esta integración, con otros sistemas de salud que ahora pueden acceder a los servicios de pruebas de GeneDx, incluyendo la secuenciación del exoma, la secuenciación del genoma completo y la secuenciación rápida del genoma completo.
La integración agiliza el proceso de pruebas genéticas, haciendo que los resultados sean más accesibles y visibles dentro de los registros de los pacientes. GeneDx tiene una experiencia significativa en pruebas genéticas, habiendo secuenciado más de 750.000 exomas y genomas, y mantiene uno de los conjuntos de datos más grandes sobre enfermedades raras. Los servicios de la compañía son confiables para 8 de cada 10 expertos en genética para las pruebas de exoma y genoma.
GeneDx (WGS)는 Epic의 전문 진단 스위트인 Aura와의 통합을 발표하며, 건강 시스템이 전자 건강 기록(EHR) 내에서 직접 유전자 서열 검사 결과를 주문하고 받을 수 있게 되었습니다. UNC Health는 이 통합을 구현한 첫 번째 건강 시스템이 되었으며, 이제 다른 건강 시스템도 GeneDx의 검사 서비스에 접근할 수 있습니다. 서비스는 엑솜 서열, 전체 유전체 서열 및 신속한 전체 유전체 서열을 포함합니다.
이 통합은 유전자 검사 프로세스를 간소화하여 결과가 환자 기록 내에서 더 접근 가능하고 가시화되도록 합니다. GeneDx는 750,000개 이상의 엑솜과 유전체를 서열 분석한 풍부한 경험을 가지고 있으며, 희귀 질환 데이터 세트 중 가장 큰 것 중 하나를 유지하고 있습니다. 이 회사의 서비스는 엑솜과 유전체 검사에 대해 10명의 유전 전문가 중 8명이 신뢰합니다.
GeneDx (WGS) a annoncé son intégration avec la suite de diagnostics spécialisée d'Epic, Aura, permettant aux systèmes de santé de commander et de recevoir des résultats de séquençage génétique directement dans leurs dossiers de santé électroniques (DSE). UNC Health devient le premier système de santé à mettre en œuvre cette intégration, d'autres systèmes de santé pouvant désormais accéder aux services de tests de GeneDx, notamment le séquençage de l'exome, le séquençage du génome entier et le séquençage rapide du génome entier.
Cette intégration rationalise le processus de test génétique, rendant les résultats plus accessibles et visibles dans les dossiers des patients. GeneDx dispose d'une expérience significative dans le test génétique, ayant séquencé plus de 750 000 exomes et génomes, et maintient l'un des plus grands ensembles de données sur les maladies rares. Les services de l'entreprise sont dignes de confiance pour 8 experts en génétique sur 10 pour les tests d'exome et de génome.
GeneDx (WGS) hat seine Integration mit Epic's Spezialdiagnosetool Aura angekündigt, was es Gesundheitssystemen ermöglicht, genetische Sequenzierungsergebnisse direkt in ihren elektronischen Gesundheitsakten (EHR) zu bestellen und zu erhalten. UNC Health ist das erste Gesundheitssystem, das diese Integration implementiert, während weitere Gesundheitssysteme nun auf die Testdienstleistungen von GeneDx zugreifen können, darunter Exomsequenzierung, gesamte Genomsequenzierung und schnelle gesamte Genomsequenzierung.
Die Integration optimiert den Prozess der genetischen Tests, wodurch die Ergebnisse innerhalb der Patientenakten zugänglicher und sichtbarer werden. GeneDx verfügt über umfassende Erfahrung im Bereich der genetischen Tests, da mehr als 750.000 Exome und Genome sequenziert wurden und es einen der größten Datensätze seltener Krankheiten unterhält. Die Dienstleistungen des Unternehmens werden von 8 von 10 Genetikexperten für Exom- und Genomtests vertraut.
- Integration with Epic's Aura platform expands market reach to health systems
- Strong market position with 80% of genetics experts using GeneDx services
- Substantial database of 750,000+ sequenced exomes and genomes
- First-mover advantage with UNC Health implementation
- None.
Insights
GeneDx's strategic integration with Epic's Aura platform marks a pivotal advancement in healthcare diagnostics infrastructure, presenting substantial growth potential for the company's $1.6B market position. This integration addresses a critical market inefficiency by streamlining genetic testing workflows within electronic health records (EHR) systems used by over 2,000 hospitals and 45,000 clinics nationwide.
The partnership creates a significant competitive moat through three key mechanisms: 1) Epic's dominant 31% market share in the EHR space, 2) GeneDx's extensive database of 750,000+ exomes and genomes and 3) High switching costs once health systems integrate these diagnostic workflows. This technological entrenchment could accelerate GeneDx's market penetration and revenue growth through increased test volumes.
The integration offers compelling unit economics. By automating order processing and results delivery, GeneDx can reduce operational costs while potentially increasing test volumes through improved accessibility. The structured data format enables secondary monetization opportunities through research partnerships and AI-driven diagnostic improvements.
For investors, this represents a strategic positioning play in the rapidly growing $17.2B genetic testing market. The partnership with Epic creates a scalable distribution channel that could significantly expand GeneDx's addressable market beyond the current genetics specialty focus into broader clinical applications. The technology integration barriers and data network effects create sustainable competitive advantages that could drive long-term value creation.
UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic Suite
“The Epic Aura integration for genetic testing offers significant advantages for both patients and providers. It streamlines the implementation process and enhances the clarity and accessibility of results within the electronic health record. With Aura, genetic test results are seamlessly integrated with other lab results, making them more visible and easier to find, rather than being hidden or located in a separate section. The structured format of the data also opens the door to numerous research and quality improvements down the line,” said Michael Adams, MD, Pediatric Genetics and Metabolism at UNC Health.
Health systems can now access the power of GeneDx’s genomic testing directly within their native EHR system, enabling clinicians to more accurately and efficiently diagnose genetic conditions and guide timely, targeted treatments. GeneDx on Epic Aura empowers healthcare providers to deliver faster and more accurate diagnoses, reducing the time to treatment and improving patient outcomes.
“GeneDx is committed to providing patient-centered solutions and our use of Aura simplifies the process for healthcare providers to ensure the first step to treatment, an accurate and fast genetic diagnosis, is easily accessible at a patient’s bedside and in the exam room,” said Katherine Stueland, President and CEO of GeneDx. “There’s a reason 8 out of 10 genetics experts rely on GeneDx for exome and genome testing, we’ve empowered thousands of clinicians with genomic insights that have changed clinical care and led to better health outcomes for their patients.”
As more health systems choose to integrate with GeneDx on Aura, the adoption of genome and exome sequencing will continue to grow, further incorporating genetic insights into routine clinical care across numerous medical specialties including pediatrics, neonatology, pediatric neurology, genetics, and more.
With unmatched experience sequencing more than 750,000 exomes and genomes – combined with millions of phenotypic datapoints – GeneDx has built one of the largest rare disease data sets. To learn more about GeneDx on Epic Aura visit: https://www.genedx.com/epic-aura.
About GeneDx
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210648009/en/
Investor Relations:
Investors@GeneDx.com
Media:
Press@GeneDx.com
Source: GeneDx
FAQ
What is the significance of GeneDx (WGS) integrating with Epic's Aura platform?
How many exomes and genomes has GeneDx (WGS) sequenced to date?
Which health system is the first to implement GeneDx's (WGS) integration with Epic Aura?
What percentage of genetics experts use GeneDx (WGS) for exome and genome testing?
What types of genetic tests are available through GeneDx's (WGS) Epic Aura integration?
